Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome

1 Jan 2012

Abstract excerpt

Fragile X syndrome (FXS) is the most common known genetic form of intellectual disability and autism spectrum disorders. FXS patients suffer a broad range of other neurological symptoms, including hyperactivity, disrupted circadian activity cycles, obsessive-compulsive behavior, and childhood seizures. The high incidence and devastating effects of this disease state make finding effective pharmacological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autism Spectrum Disorder Research
Share to Genetics and Neurodevelopmental Disorders
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22685676
DOI: 10.1155/2012/124548

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X SyndromePMID 22685676Read ↗

Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.Semantic proximity Read ↗

High MMP‐9 activity levels in fragile X syndrome are lowered by minocyclineSemantic proximity Read ↗

Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)Semantic proximity Read ↗

Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.Semantic proximity Read ↗

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfoldingSemantic proximity Read ↗

Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.Semantic proximity Read ↗

Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.Semantic proximity Read ↗

The TIMPs tango with MMPs and more in the central nervous systemSemantic proximity Read ↗

The Protective Effect of Minocycline in a Paraquat-Induced Parkinson's Disease Model inDrosophilais Modified in Altered Genetic BackgroundsSemantic proximity Read ↗

Minocycline for Huntington’s disease: An open label studySemantic proximity Read ↗

Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site.Semantic proximity Read ↗

Glucocorticoids Alter Craniofacial Development and Increase Expression and Activity of Matrix Metalloproteinases in Developing Zebrafish (Danio rerio)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.